8-K

SECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 28, 2007

MB Software Corporation

(Exact name of registrant as specified in its charter)

Texas	0-11808	59-2219994
(State or other jurisdiction	(Commission File	(IRS Employer
incorporation)	Number)	Identification No.)

777 Main Street, Suite 3100, Fort Worth, Texas	76102
(Address of principal executive offices)	(Zip Code)

Registrant's telephone number, including area code 817-820-7080

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

[_] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

[_] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

[_] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

[_] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 1.01 Entry into a Material Definitive Agreement

Effective November 28, 2007, Wound Care Innovations, L.L.C., a Nevada limited liability company and MB Software's wholly owned subsidiary ("WCI"), entered into separate exclusive license agreements with Applied Nutritionals LLC, a Delaware limited liability company ("AN"), and its founder George Petitio, pursuant to which WCI has obtained the exclusive world-wide license to certain patented technologies and processes related to CellerateRx^TM, an advanced collagen based wound care product formulation.

WCI has been marketing and selling CellerateRx over the past three years under the terms of a distribution agreement that was terminated in 2005. These new licenses are limited to the human health care market for external wound care, and include any new product developments based on the licensed patent and processes. The term of these licenses extends through the life of the licensed patent.

In consideration for the licenses, WCI has agreed to pay to AN and Mr. Petito the following, beginning January 3, 2008: (a) an advance royalty of $100,000 in the aggregate, (b) an aggregate royalty of fifteen percent (15%) of gross sales occurring during the first year of the license; (c) an additional advance royalty of $400,000, in the aggregate, on January 3, 2009; plus (d) an aggregate royalty of three percent (3%) of gross sales for all sales occurring after the payment of the $400,000 advance royalty. In addition, after January 3, 2009, WCI must maintain a minimum aggregate annual royalty payment of $375,000.

All royalties, other than the advance royalty payments described above, are due and payable on a calendar quarterly basis on or before the forty-fifth (45^th) day of the month immediately following the calendar quarter in which gross sales are received.

In addition to the license agreements, WCI also entered into an exclusive manufacturing agreement with AN pursuant to which AN will manufacture all CellerateRx and related products for WCI. The term of the manufacturing agreement extends through the life of the licensed patent; provided that upon the acquisition of WCI by a party with annual revenues of at least $100,000,000 or a market capitalization of at least $200,000,000, the acquiror may terminate the manufacturing agreement.

In connection with the above transaction, WCI will also issue to Mr. Petito 1,000 shares of a newly designated preferred stock. The preferred stock will automatically convert into an aggregate of 5,100,000 shares of common stock upon the filing by MB Software of an amendment to its Articles of Incorporation increasing its authorized number of shares of common stock from 20,000,000 to 100,000,000, and participate with the common stock, on an as converted basis, with respect to dividends and liquidation, and votes together with the common stock as a single class, as if such shares of preferred stock had been converted.

MB Software has received consents from shareholders holding a majority of its outstanding shares of common stock approving the amendment.

2

The descriptions of the aforementioned transactions are qualified in their entirety by reference to copies of the applicable agreements filed as exhibits to this Form 8-K and incorporated herein by this reference.

Item 3.02 Unregistered Sales of Equity Securities.

See Item 1.01

Item 5.03 Amendments to Articles of Incorporation or Bylaws, Change in Fiscal Year.

See Item 1.01. Pursuant to MB Software's Articles of Incorporation, the company's board of directors may establish one or more series of preferred stock. The preferred stock described under Item 1.01 was established by the company's board of directors pursuant to a unanimous written consent on October 31, 2007.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

Exhibit Number	Description
3.1(i)	Certificate of Designations, Number Voting Powers, Preferences and Rights of Series A Convertible Preferred Stock of MB Software Corporation.
10.1	Exclusive Patent and Trademark License dated as of November 28, 2007, by and between Wound Care Innovations, L.L.C. and Applied Nutritionals, LLC.
10.2	Exclusive License dated as of November 28, 2007, by and between Wound Care Innovations, L.L.C. and George Petito.
10.3	Manufacturing Agreement dated as of November 28, 2007, by and between Wound Care Innovations, L.L.C. and Applied Nutritionals, LLC.
99.1	Press release dated November 29, 2007.

3

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	MB Software Corporation
Date: November 29, 2007
	/s/Scott A. Haire
	Scott A. Haire, Chairman of the
	Board, Chief Executive Officer
	And President (Principal Financial
	Officer)

4

EX-3.1

2

3

EX-10.1

2

3

4

5

6

7

8

9

10

11

C-1

EX-10.2

2

3

4

5

6

7

8

9

10

11

A-1

C-1

B-2

EX-10.3

2

3

4

5

6

7

8

9

10

11

12

A-1

B-1

C-1

EX-99.1

MBSB Announces Exclusive Worldwide Human Health Care License Rights to its External Wound Care Products

FORT WORTH, TX -- (MARKET WIRE) – 11/29/07 -- MB Software Corporation (OTCBB: MBSB) announced today that its wholly owned subsidiary Wound Care Innovations LLC has entered into enhanced agreements with the licensors of its wound care products under which the company now has the exclusive worldwide license to market and sell the current products and any new developed products for the human health care market for external wound care.

The company has been actively marketing the CellerateRx® brand of products within the United States to the human health care market and foresees even greater growth with this development. "We are very pleased with our enhanced agreements and believe they strengthen our ability to grow our company faster as we now have the ability to offer our products to the rest of the world," said Scott Haire, the company's Chairman. "These enhanced agreements coupled with our recent announcement of evidence-based studies on the Cellerate products will give us greater momentum going into 2008 and beyond."

The company's Vice president of Corporate Development, Cathy Bradshaw further noted, "our current Cellerate products are FDA cleared for marketing for all wounds except 3rd degree burns, and are effective in all wound phases and states. CellerateRX is peerless in its simplicity of use and application as an advanced therapy. It reduces the costs of wound care therapies and is safe, biocompatible and biodegradable. It is important to note that our product can be used with all other current wound care therapies. We continue to have great results with the product and now we will expand our sales efforts to the worldwide human health care arena."

CellerateRX is available in two forms, a powder and a gel, and both products feature HCPCS codes for reimbursement in the USA.

About MB Software Corporation:

MB Software Corporation (OTCBB: MBSB), with its corporate headquarters in Fort Worth, Texas, markets and distributes wound care products to the healthcare market under patented technology licensed to the Company. The Company is positioned and seeks to be a leading provider of wound care products. For more information on the Company please visit the Company's Website at www.CellerateRX.com .

"Safe Harbor" Statement: Under The Private Securities Litigation Reform Act of 1995: The statements in the press release that relate to the company's expectations with regard to the future impact on the company's results from new products in development are "forward-looking statements," within the meaning of the Private Securities Litigation Reform Act of 1995. Since this information may contain statements that involve risk and uncertainties and are subject to change at any time, the company's actual results may differ materially from expected results. This document may contain forward-looking statements concerning the Company's operations, current and future performance and financial condition. These items involve risks and uncertainties such as product demand, market and customer acceptance, the effect of economic conditions, competition, pricing, the ability to consummate and integrate acquisitions, and other risks and uncertainties detailed in the Company's SEC filings. The Company undertakes no obligation to revise any of these statements to reflect the future circumstances or the occurrence of unanticipated events.

MEDIA CONTACT:

MEDIA CONTACT:
Mr. Jonathan Pappie	Capital Pros Network
mrpappie@yahoo.com	4037-A Phelan Road
jpappie@capitalpros.com	Suite 107
	Phelan, CA 92371
	Phone: 760-669-9521
	Fax: 760-281-9130
	www.capitalpros.com